SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8
http://www.w3.org/2000/01/rdf-schema#comment
"Acquired resistance in patients with initial treatment benefit is mainly explained by polyclonal emergence of RAS BRAF and EGFR mutations in circulating tumor DNA."
xsd:string
http://purl.uniprot.org/uniprot/#_C52E480C533684E31E7B097AAA736BDD3B9150CBF51AA602B1D1B0899C7A9E5CA6B98288A4538154720B9FA7236D9B71
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8
http://purl.uniprot.org/uniprot/P01116
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8
http://purl.uniprot.org/uniprot/#_P01116-mappedCitation-31350822
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/0A322472A8CAE497B2C3E8FF8394B69DCA33F8E7C6AEF224FFD04696F35F922B4B17EE471CB709F90F88F7A3C6C9E5D8